Gold's recent underperformance is seen as a temporary pause, not the end of its bull market, says Goldman Sachs' Anthony Kim. Key factors include uncertainty over the new Fed chair's policies and disruptions from the Iran conflict affecting gold reserves. Central banks continue strong gold buying, supporting prices, with Goldman Sachs forecasting gold to reach $4,900 per ounce by end of 2026. Investors are advised to consider buying near $4,000 as data around Fed decisions unfold, with volatility expected due to increased use of gold derivatives for hedging.
Chewy will report its Q2 2026 earnings on September 9, with analysts expecting earnings per share (EPS) of $0.36, a 9.1% increase year-over-year, and revenue of $3.32 billion, up 6.8%. Growth is driven by its Autoship subscription program and expansi...
Tarsus Pharmaceuticals recently acquired Alkeus Pharmaceuticals, gaining worldwide rights to gildeuretinol, a promising Phase 3 drug for Stargardt's disease, which currently lacks FDA-approved treatments. Analyst Jefferies raised Tarsus' price target...
The Trade Desk is undergoing restructuring with a 15% workforce reduction costing up to $51 million, following its removal from the S&P 500 index which caused a 2% stock drop. Despite these challenges, the company shows strong financial health, repor...
GameStop reported Q2 2026 revenue of $790.20 million, beating analyst estimates but showing a 19% year-over-year decline due to a strong prior year and strategic store closures. The company's Collectibles segment grew 57% to $356.30 million, offsetti...
Raymond James analyst Michael Freeman raised Dyne Therapeutics' price target to $37, suggesting an 80.75% upside from its current price around $20.60. The clinical-stage biotech is advancing treatments for muscle diseases like Myotonic Dystrophy Type...
